EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Lymphoscintigraphy Using Tilmanocept Detects Multiple Sentinel Lymph Nodes in Melanoma Patients

Daniel M Balkin, Gregory J Tranah, Frederick Wang, Cristina O'Donoghue, Emily A Morell, Caitlin Porubsky, Mehdi Nosrati, Edith M Vaquero, HanKyul Kim, Michael J Carr, Jaime L Montilla-Soler, Max C Wu und 4 weitere

Cancer Control · 2023

DOI: 10.1177/10732748231153775 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Control, 2023. Verfasst von Daniel M Balkin und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Plastic and Oral Surgery, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA. Hauptthemen laut MEDLINE: Sentinel Lymph Node, Melanoma, Skin Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Cardinal Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Technetium-99m-labeled Tilmanocept, a multivalent mannose, is readily internalized by the CD206 surface receptor on macrophages and dendritic cells which are abundantly present in lymph nodes. We want to examine the drainage patterns of Technetium-99m-labeled Tilmanocept to sentinel lymph nodes (SLNs) in melanoma patients following the 10% rule.

Methods

Multi-center retrospective review of patients with cutaneous melanoma undergoing SLN biopsy using Technetium-99m-labeled Tilmanocept between 2008 and 2014 was conducted. Statistical methods were used for data analyses.

Results

Of the 564 patients (mean age of 60.3 and 62% male) with preoperative lymphoscintigraphy showing at least one SLN, several primary tumor sites were included: 27% head/neck, 33% trunk, 21% upper extremity and 19% lower extremity. For the head/neck primary site, 36.5% of patients had multiple draining basins; for the trunk site, 36.4% of patients; for the upper extremity site, 13% of patients; and for the lower extremity, 27.4% of patients. A median of 3 (range 1-18) SLNs were identified and resected. Overall, 78% of patients had >1 SLN identified by Technetium-99m-labeled Tilmanocept. In a multivariate model, patients with >1 SLN were significantly associated with age, Breslow depth, tumor location and higher AJCC tumor stage. A total of 17.7% of patients (100/564) had a positive SLN identified. A total of 145 positive SLNs were identified out of 1,812 SLNs with a positive SLN rate of 8%. Positive SLN status was significantly associated with younger age, greater Breslow depth, mitosis rate, higher AJCC tumor stage, presence of ulceration and angiolymphatic invasion.

Conclusions

Using the 10% rule, Technetium-99m-labeled Tilmanocept detects multiple SLNs in most melanoma patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sentinel Lymph NodeMelanomaSkin NeoplasmsHumansMaleMiddle AgedFemaleLymphoscintigraphySentinel Lymph Node BiopsyRadiopharmaceuticalsTechnetium Tc 99m PentetateTechnetiumLymphatic MetastasisLymph Nodes

Stichwörter der Autor:innen

melanoma lymphatic drainagemelanoma sentinel lymph nodestilmanocept (lymphoseek)

Substanzen

RadiopharmaceuticalsTechnetium Tc 99m PentetateTechnetium

Autor:innen und Institutionen

  • Department of Plastic and Oral Surgery, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
  • Center for Melanoma Research and Treatment, California Pacific Medical Center Research Institute, San Francisco, CA, USA.
  • Kaiser Permanente Woodland Hills Medical Center, Woodland Hills, CA, USA.
  • Department of Cutaneous Oncology, 25301Moffitt Cancer Center, Tampa, FL, USA.
  • Department of Pediatrics, Divisions of Pediatric Critical Care and Pediatric Cardiology, University of California San Francisco, San Francisco, CA, USA.
  • Philadelphia College of Osteopathic Medicine/North Fulton Hospital Medical Campus, Roswell, GA, USA.

ORCID-Profile: Stanley P Leong

Förderung

  • Cardinal Health

Zitieren

APA

Balkin, D. M., Tranah, G. J., Wang, F., O'Donoghue, C., Morell, E. A., Porubsky, C., Nosrati, M., Vaquero, E. M., Kim, H., Carr, M. J., Montilla-Soler, J. L., Wu, M. C., Torre, D. M., Kashani-Sabet, M., Zager, J. S., & Leong, S. P. (2023). Lymphoscintigraphy Using Tilmanocept Detects Multiple Sentinel Lymph Nodes in Melanoma Patients. Cancer Control. https://doi.org/10.1177/10732748231153775

Vancouver

Balkin DM, Tranah GJ, Wang F, O'Donoghue C, Morell EA, Porubsky C, et al. Lymphoscintigraphy Using Tilmanocept Detects Multiple Sentinel Lymph Nodes in Melanoma Patients. Cancer Control. 2023. doi:10.1177/10732748231153775

BibTeX
@article{Balkin2023,
  author = {Balkin, Daniel M and Tranah, Gregory J and Wang, Frederick and O'Donoghue, Cristina and Morell, Emily A and Porubsky, Caitlin and Nosrati, Mehdi and Vaquero, Edith M and Kim, HanKyul and Carr, Michael J and Montilla-Soler, Jaime L and Wu, Max C and Torre, Donald M and Kashani-Sabet, Mohammed and Zager, Jonathan S and Leong, Stanley P},
  title = {Lymphoscintigraphy Using Tilmanocept Detects Multiple Sentinel Lymph Nodes in Melanoma Patients},
  journal = {Cancer Control},
  year = {2023},
  doi = {10.1177/10732748231153775}
}
Kostenlos starten →